Trial Profile
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Outpatient Study Evaluating the Pharmacokinetics, Efficacy, and Safety of Baricitinib in Pediatric Patients With Moderate to Severe Atopic Dermatitis
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 23 Apr 2024
Price :
$35
*
At a glance
- Drugs Baricitinib (Primary)
- Indications Atopic dermatitis
- Focus Pharmacokinetics; Registrational; Therapeutic Use
- Acronyms BREEZE-AD-PEDS
- Sponsors Eli Lilly and Company; Eli Lilly and Company (India) Pvt. Ltd
- 09 Jun 2023 Status changed from recruiting to active, no longer recruiting.
- 17 Aug 2022 Planned End Date changed from 15 Jan 2027 to 22 May 2026.
- 18 Feb 2022 Planned primary completion date changed from 21 Jul 2022 to 25 Apr 2022.